EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments EyePoint (Nasdaq: EYPT) reported Q4 and full-year 2025 results and corporate updates on March 4, 2026. Key clinical milestones: Phase 3 wet AMD topline readouts begin mid-2026; DME Phase 3 topline data expected H2 2027. Financials: $306 million cash and investments at year-end, runway into Q4 2027; FY 2025 net revenue $31.4M versus $43.3M prior year; FY 2025 net loss $232.0M (GAAP). Corporate: appointed CCO Michael Campbell, issued U.S. patent extending DURAVYU coverage to 2043, completed $172.5M offering and finished registration manufacturing batches for NDA support.

#EYPT EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

www.stocktitan.net/news/EYPT/eye-point-repo...

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema EyePoint (Nasdaq: EYPT) announced first patients dosed in two global Phase 3 trials (COMO and CAPRI) of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema (DME) on March 2, 2026. Each randomized, aflibercept-controlled non-inferiority trial will enroll ~240 patients with DURAVYU 2.7mg re-dosed every six months.Key points: topline DME data anticipated in 2H 2027; primary endpoint is non-inferior change in BCVA at weeks 52 and 56; secondary endpoints include safety, treatment burden reduction, supplemental aflibercept use, and OCT anatomy. Program aligned with FDA and EMA.

#EYPT EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

www.stocktitan.net/news/EYPT/eye-point-anno...

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 – Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44 th

#EYPT EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

www.stocktitan.net/news/EYPT/eye-point-repo...

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration EyePoint (Nasdaq: EYPT) announced a positive recommendation from an independent Data Safety Monitoring Committee (DSMC) after its second scheduled review of the pivotal Phase 3 LUGANO and LUCIA trials for DURAVYU in wet age-related macular degeneration (wet AMD) on Nov 19, 2025.The DSMC found no safety signals and recommended both trials continue with no protocol changes. Enrollment is complete with over 900 patients. As of the Sept 29, 2025 cutoff all patients reached Week 8 and ~25% received a Week 32 redosing. Topline 56-week LUGANO data are on track for mid-2026, with LUCIA to closely follow.

#EYPT EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

www.stocktitan.net/news/EYPT/eye-point-anno...

#EYPT EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

www.stocktitan.net/news/EYPT/eye-point-repo...

Trade Alerts, Wednesday October 15, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Wed Oct 15th - #EXPW #KROS #YDKG #WPRT #SDA #PXLW #LNKB #LGO #KARO #EYPT #CBAT #BMR - More: crystalequityresearch.com/trade-alerts... - #smallcap

EyePoint Announces Pricing of Public Offering EyePoint (NASDAQ: EYPT) priced an underwritten public offering on Oct 14, 2025 of 11,000,000 common shares at $12.00 per share and pre-funded warrants to purchase up to 1,500,000 shares at $11.999 each.The aggregate gross proceeds are expected to be approximately $150 million before underwriting discounts, with closing expected on or about Oct 16, 2025. EyePoint granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. Net proceeds are intended to fund clinical development of DURAVYU for wet AMD and DME, earlier-stage pipeline work, and general corporate purposes.

#EYPT EyePoint Announces Pricing of Public Offering

www.stocktitan.net/news/EYPT/eye-point-anno...

EyePoint Announces Proposed Public Offering of Common Stock EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten

#EYPT EyePoint Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/EYPT/eye-point-anno...

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema – DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data demonstrates that vorolanib, the active drug in DURAVYU, inhibits both VEGF-mediated

#EYPT EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

www.stocktitan.net/news/EYPT/eye-point-anno...

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 2025 financial results and significant progress in its DURAVYU™ development program for wet AMD. The company successfully completed enrollment for two Phase 3 trials: LUGANO (432 U.S. patients) and LUCIA (over 400 global patients), both achieving unprecedented seven-month enrollment periods.Q2 2025 financial results showed revenue of $5.3 million, down from $9.5 million in Q2 2024. The company reported a net loss of $59.4 million ($0.85 per share). EyePoint maintains a strong financial position with $256 million in cash, providing runway into 2027, beyond the expected Phase 3 topline data readouts in mid-2026.The company's Northbridge, MA manufacturing facility is now operational and producing DURAVYU registration batches in preparation for potential FDA approval.

#EYPT EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

www.stocktitan.net/news/EYPT/eye-point-repo...

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration EyePoint Pharmaceuticals (Nasdaq: EYPT) has completed enrollment for its pivotal Phase 3 program testing DURAVYU™ for wet age-related macular degeneration (wet AMD). The program consists of two trials: LUCIA and LUGANO, collectively enrolling over 800 patients, making it one of the fastest-enrolling Phase 3 programs in wet AMD history.The trials evaluate DURAVYU's 6-month redosing schedule against aflibercept, with topline data expected in mid-2026. The Data Safety Monitoring Committee has confirmed DURAVYU's safety profile, consistent with previous trials showing no related serious adverse events in over 190 patients. The Phase 3 program, developed with FDA and EMA alignment, aims to bring the first sustained-release TKI treatment for wet AMD to market.

#EYPT EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

www.stocktitan.net/news/EYPT/eye-point-comp...

Clinical Trial Milestone: EyePoint's Revolutionary 6-Month Eye Treatment Completes Phase 3 Enrollment 400+ patients enrolled in groundbreaking wet AMD trial testing 6-month dosing treatment. First sustained-release TKI shows promise for revolutionizing eye care. See timeline.

#EYPT EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

www.stocktitan.net/news/EYPT/eye-point-comp...

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals (EYPT) reported strong progress in Q1 2025, with their Phase 3 DURAVYU trials for wet AMD showing exceptional enrollment rates. The LUGANO trial has reached over 90% enrollment and LUCIA over 50%, with both expected to complete enrollment in 2H 2025. The company reported total net revenue of $24.5 million, up from $11.7 million in Q1 2024, primarily driven by YUTIQ licensing revenue.The company maintains a strong financial position with $318.2 million in cash and equivalents, providing runway into 2027. Operating expenses increased to $73.3 million, mainly due to accelerated trial enrollment. Net loss was $45.2 million ($0.65 per share). DURAVYU demonstrated promising results in Phase 2 VERONA trial for diabetic macular edema, showing significant vision improvement and fluid reduction compared to aflibercept control.

#EYPT EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

www.stocktitan.net/news/EYPT/eye-point-repo...

EyePoint Reports Mixed Earnings: Can Its $371M War Chest and Promising Eye Disease Pipeline Deliver Returns? EyePoint reports $11.6M Q4 revenue with strong $371M cash position extending runway into 2027. DURAVYU wet AMD trials exceed 50% enrollment with positive DME trial results.

#EYPT EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

www.stocktitan.net/news/EYPT/eye-point-repo...

Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds EyePoint's DURAVYU shows superior efficacy in DME treatment with 73% of patients remaining supplement-free vs. 50% for aflibercept, while achieving +7.1 letter vision improvement.

#EYPT EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

www.stocktitan.net/news/EYPT/eye-point-anno...

BREAKING NEWS: ( NASDAQ: #EYPT ) Long Term Trading Analysis for (EYPT)

EyePoint's DURAVYU Shows Strong DME Trial Results, Reports $370M Cash Position for 2025 EyePoint reports positive Phase 2 DME trial data for DURAVYU, with significant vision improvements. Phase 3 trials advance as company strengthens operations with new facility.

#EYPT EyePoint Provides Company Update and Anticipated Development Milestones for 2025

www.stocktitan.net/news/EYPT/eye-point-prov...

Breaking News: ( NASDAQ: #EYPT ) EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

#StockMarket #News

#EYPT EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

www.stocktitan.net/news/EYPT/eye-point-phar...

Just In: ( NASDAQ: #EYPT ) EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of Equities by Percentage Gain on 10/28

#StockMarket #News

NEWS: ( NASDAQ: #EYPT ) Buy Recommendation Issued On EYPT By Jefferies

#StockMarket #News